OralParenteralDosed ingredient Cosmetic cross-reference

Retinol

CAS 68-26-8

Retinol (CAS 68-26-8) is a Phase 4 pharmaceutical compound with 16 bioactivity targets and 1,884 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
22
SOURCE DrugCentral
Adverse signals
1,884
SOURCE IUPHAR/BPS
PubMed IDs
1
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Retinol
CAS Number
68-26-8
UNII
G2SH0XKK91
InChIKey
FPIPGXGPPPQFEQ-OVSJKPMPSA-N
ChEMBL ID
CHEMBL986
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
VITAMIN AVITAMIN A PALMITATEAquasol AAvita
dosed ingredientnatural productoralparenteral
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL986 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 22 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 38421.50465116279 nM 71 -
- AC50 15314.285714285714 nM 63 -
- GI50 23089.484528301884 nM 53 -
- IC50 18842.5 nM 4 -
- Kd 122 nM 4 -
- Ki 8.3 nM 1 -
11-cis retinol dehydrogenase
Enzyme
 - - - Homo sapiens
Retinol dehydrogenase 12
Enzyme
 - - - Homo sapiens
Retinol dehydrogenase 13
Enzyme
 - - - Homo sapiens
Retinol-binding protein 3
Surface antigen
 - - - Homo sapiens
Retinol-binding protein 5
Cytosolic other
 - - - Homo sapiens
Retinoid-binding protein 7
Cytosolic other
 - - - Homo sapiens
Retinol-binding protein 4
Secreted
 Kd 6.74 - Homo sapiens
Retinol-binding protein 2
Cytosolic other
 - - - Homo sapiens
Retinal dehydrogenase 2
Enzyme
 - - - Homo sapiens
Retinal dehydrogenase 1
Enzyme
 - - - Homo sapiens
Retinaldehyde-binding protein 1
Transporter
 - - - Homo sapiens
Beta-lactoglobulin
Unclassified
 Kd 7.44 - Bos taurus
Retinol-binding protein 1
Cytosolic other
 - - - Homo sapiens
Amyloid beta A4 protein
Unclassified
 IC50 6.75 - Homo sapiens
Nuclear receptor subfamily 2 group C member 2
Nuclear other
 EC50 4.71 - Homo sapiens
Alpha-synuclein
Transporter
 IC50 6.72 - Homo sapiens
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Off label use 516 164.291 10053762
Pemphigus 3 160.688 10034280
Completed suicide 12 157.747 10010144
Synovitis 10 144.194 10042868
Contraindicated product administered 30 136.225 10078504
Hand deformity 4 134.488 10061194
Toxicity to various agents 120 131.127 10070863
Systemic lupus erythematosus 21 130.764 10042945
Product dose omission issue 612 129.753 10084406
Product use in unapproved indication 60 125.83 10076476
Diarrhoea 1451 120.671 10012735
Drug abuse 7 114.311 10013654
Drug ineffective 824 108.338 10013709
Pleural thickening 56 102.953 10035616
Gastrooesophageal reflux disease 299 102.392 10017885
Glossodynia 23 102.069 10018388
Fatigue 1580 100.311 10016256
Presbyacusis 53 100.029 10036626
Blood magnesium increased 58 99.647 10005655
Anti-cyclic citrullinated peptide antibody positive 3 95.993 10068798
Product use issue 76 93.858 10076309
Maternal exposure during pregnancy 46 88.758 10071408
Muscle spasms 404 87.216 10028334
Full blood count decreased 138 85.99 10017413
Pneumonia aspiration 194 82.919 10035669
Pleural fibrosis 55 82.362 10035600
Fall 797 76.448 10016173
Infusion related reaction 105 74.127 10051792
Pericarditis 21 73.017 10034484
Drug interaction 179 72.708 10013710
Intentional overdose 10 69.171 10022523
Epigastric discomfort 61 67.713 10053155
Infective pulmonary exacerbation of cystic fibrosis 73 67.399 10070608
Deafness neurosensory 58 66.741 10011891
Plasma cell myeloma 176 66.237 10035226
Therapy cessation 129 62.986 10065154
Duodenal ulcer perforation 6 61.937 10013849
Laboratory test abnormal 126 60.477 10023547
Cyst 79 59.872 10011732
Wound 46 59.722 10052428
Asthenia 797 59.658 10003549
Lower respiratory tract infection 37 58.358 10024968
Psoriasis 231 57.457 10037153
Dry eye 132 57.268 10013774
Unevaluable event 176 56.807 10062355
Neuropathy peripheral 326 56.319 10029331
Device expulsion 99 54.189 10012578
Overdose 65 54.121 10033295
General physical health deterioration 125 53.176 10049438
Dizziness 808 52.468 10013573

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 1 interaction

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
Testicular receptor 4
NR2C2
 Full agonist 4.710000038146973 pEC50 21068381
SOURCE NLM RxNorm 12 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
VITAMIN A 11246 SU MTHSPL
Retinol 11246 SU MTHSPL
RETINOL 11246 SU MTHSPL
Vitamin A 11246 SU MTHSPL
vitamin A 11246 SU MTHSPL
VITAMIN A PALMITATE 35406 SU MTHSPL
Vitamin A Palmitate 35406 SU MTHSPL
vitamin a palmitate 35406 SU MTHSPL
vitamin A 11246 IN RXNORM
vitamin A palmitate 35406 PIN RXNORM
Aquasol A 202783 BN RXNORM
Avita 215492 BN RXNORM
SOURCE SIDER 4 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Anaphylactic shock retinol LLT C0002792
Anaphylactic shock retinol PT C0002792
Hypersensitivity retinol LLT C0020517
Hypersensitivity retinol PT C0020517
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Retinol used for in pharmaceutical contexts?

Retinol (CAS 68-26-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Retinol?

Retinol has 1,884 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Off label use, Pemphigus, Completed suicide, Synovitis, Contraindicated product administered. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Retinol also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Retinol with EU status "restricted".

What clinical phase is Retinol in?

Retinol is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Retinol?

Retinol has 22 bioactivity rows in this page query. Rendered target entries include 11-cis retinol dehydrogenase, Retinol dehydrogenase 12, Retinol dehydrogenase 13, Retinol-binding protein 3, Retinol-binding protein 5.